Internal Medicine · Beaumont, TX
NPI
1427002823
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
3570 College St, Suite 180
Beaumont, TX, 77701
Phone (409) 833-9797
Groups this clinician bills Medicare through
Medicare paid, 2024
$73K
3,211 services
Medicare patients, 2024
346
Average age 73
Drug cost, 2024
$4.2M
10,378 prescriptions
Company payments, 2025
$477
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jaweed Akhter was code 36415 (venipuncture blood collection), 309 times for 169 patients. In total Jaweed Akhter billed 3,211 services in 41 codes, and Medicare paid $73K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-09-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 36415 Venipuncture Blood Collection | Office | 309 | 169 | $8.57 | $2,647 |
| 99214 Office E&M - Established | Office | 299 | 164 | $77.86 | $23K |
| 80048 Clinical Chemistry | Office | 286 | 163 | $8.28 | $2,368 |
| 80076 Clinical Chemistry | Office | 260 | 144 | $8.01 | $2,083 |
| 80061 Clinical Chemistry | Office | 259 | 143 | $13.12 | $3,398 |
| 85025 Blood Count | Office | 242 | 142 | $7.61 | $1,842 |
| 82043 Clinical Chemistry | Office | 242 | 135 | $5.64 | $1,365 |
| 82570 Clinical Chemistry | Office | 241 | 134 | $5.08 | $1,224 |
| 83036 Blood Count | Office | 203 | 138 | $9.52 | $1,933 |
| 82962 Clinical Chemistry | Office | 183 | 115 | $3.21 | $587 |
| 99232 Hospital E&M - Subsequent | Facility | 146 | 77 | $58.30 | $8,512 |
| 81015 Clinical Chemistry | Office | 118 | 83 | $2.99 | $353 |
| 81003 Clinical Chemistry | Office | 92 | 70 | $2.18 | $200 |
| 99233 Hospital E&M - Subsequent | Facility | 86 | 51 | $89.10 | $7,663 |
| 99239 Hospital Discharge Management | Facility | 58 | 56 | $84.54 | $4,903 |
By year: 2022 $97K for 4,859 services; 2023 $89K for 3,959 services; 2024 $73K for 3,211 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 309 | 169 | $8.57 | $2,647 |
| 80048 Clinical Chemistry | 286 | 163 | $8.28 | $2,368 |
| 80076 Clinical Chemistry | 260 | 144 | $8.01 | $2,083 |
| 80061 Clinical Chemistry | 259 | 143 | $13.12 | $3,398 |
| 85025 Blood Count | 242 | 142 | $7.61 | $1,842 |
| 82043 Clinical Chemistry | 242 | 135 | $5.64 | $1,365 |
| 82570 Clinical Chemistry | 241 | 134 | $5.08 | $1,224 |
| 83036 Blood Count | 203 | 138 | $9.52 | $1,933 |
| 82962 Clinical Chemistry | 183 | 115 | $3.21 | $587 |
| 81015 Clinical Chemistry | 118 | 83 | $2.99 | $353 |
Medicare prescription drug claims, 2024
In 2024, the drug Jaweed Akhter prescribed most often to Medicare patients was Ozempic (Semaglutide), with 812 prescriptions and refills. In total Jaweed Akhter wrote 10,378 Medicare prescriptions that cost $4.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 812 | 1,426 | 209 | $1.3M |
| Metformin Hcl Generic | 810 | 2,105 | 234 | $5,792 |
| Tresiba Flextouch U-200 Insulin Degludec | 726 | 1,616 | 244 | $885K |
| Atorvastatin Calcium Generic | 654 | 1,679 | 192 | $4,944 |
| Glipizide Generic | 528 | 1,350 | 179 | $3,552 |
| Levothyroxine Sodium Generic | 473 | 1,294 | 144 | $3,858 |
| Novolog Flexpen Insulin Aspart | 412 | 812 | 135 | $113K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 324 | 773 | 129 | $32K |
| Gabapentin Generic | 280 | 598 | 83 | $3,398 |
| Farxiga Dapagliflozin Propanediol | 253 | 501 | 73 | $271K |
| Jardiance Empagliflozin | 217 | 426 | 56 | $237K |
| Losartan Potassium Generic | 215 | 540 | 61 | $1,491 |
| Amlodipine Besylate Generic | 185 | 445 | 52 | $917 |
| Glipizide Er Glipizide | 167 | 467 | 63 | $2,262 |
| Rosuvastatin Calcium Generic | 160 | 388 | 48 | $2,967 |
Brand drugs: 4,178 claims; generic drugs: 5,275 claims; opioid claims: 19.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jaweed Akhter $477 ($477 in general payments such as food, travel and fees) from 10 companies. The largest payer was Dexcom, Inc. with $137.
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. DXCM | 8 | $137 |
| Mannkind Corporation MNKD | 4 | $121 |
| Corcept Therapeutics CORT | 3 | $48.75 |
| Sequel Med Tech, LLC | 2 | $45.96 |
| Novo Nordisk Inc NVO | 2 | $33.83 |
| Beta Bionics, Inc. BBNX | 2 | $22.38 |
| Lilly USA, LLC LLY | 1 | $18.35 |
| Amgen Inc. AMGN | 1 | $18.04 |
| Madrigal Pharmaceuticals MDGL | 1 | $17.86 |
| Xeris Pharmaceuticals, Inc. | 1 | $13.95 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.